Lp-PLA2 (Lipoprotein-Associated Phospholipase A2) Deficiency Lowers Cholesterol Levels and Protects Against Atherosclerosis in Rabbits

被引:6
|
作者
Chen, Jiahuan [1 ]
Zhang, Huanyu [1 ]
Li, Linquan [1 ]
Zhang, Xinwei [1 ]
Zhao, Dazhong [1 ]
Wang, Lingyu [1 ]
Wang, Jiaqi [1 ]
Yang, Ping [1 ,2 ]
Sun, Huan [2 ]
Liu, Kun [2 ]
Chen, Weiwei [2 ]
Li, Lin
Lin, Feng [1 ]
Li, Zhanjun [1 ]
Chen, Y. Eugene [4 ]
Zhang, Jifeng [4 ]
Pang, Daxin [1 ,5 ]
Ouyang, Hongsheng [1 ,5 ]
He, Yuquan [2 ,8 ]
Fan, Jianglin [3 ,7 ]
Tang, Xiaochun [1 ,5 ,6 ]
机构
[1] Jilin Univ, Coll Anim Sci, Changchun, Jilin, Peoples R China
[2] Jilin Univ, Dept Cardiol, China Japan Union Hosp, Changchun, Peoples R China
[3] Univ Yamanashi, Fac Med, Grad Sch Med Sci, Dept Mol Pathol, Kofu, Yamanashi, Japan
[4] Univ Michigan, Ctr Adv Models Translat Sci & Therapeut, Dept Internal Med, Med Ctr, Ann Arbor, MI USA
[5] Jilin Univ, Chongqing Res Inst, Chongqing, Peoples R China
[6] Jilin Univ, Coll Anim Sci, 5333 Xian Rd, Changchun, Peoples R China
[7] Univ Yamanashi, Fac Med, Grad Sch Med Sci, Dept Mol Pathol, Kofu, Yamanashi, Japan
[8] Jilin Univ, Dept Cardiol, China Japan Union Hosp, Changchun, Peoples R China
基金
国家重点研发计划;
关键词
atherosclerosis; cardiovascular diseases; inflammation; lipoproteins; rabbits; ACTIVATING-FACTOR-ACETYLHYDROLASE; CORONARY-ARTERY-DISEASE; PAF-AH ACTIVITY; IMPROVES HYPERLIPIDEMIA; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; DARAPLADIB; RISK; INFLAMMATION; EVENTS;
D O I
10.1161/ATVBAHA.122.317898
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background:Elevated plasma Lp-PLA(2) (lipoprotein-associated phospholipase A(2)) activity is closely associated with an increased risk of cardiovascular events. However, whether and how Lp-PLA(2) is directly involved in the pathogenesis of atherosclerosis is still unclear. To examine the hypothesis that Lp-PLA(2) could be a potential preventative target of atherosclerosis, we generated Lp-PLA(2) knockout rabbits and investigated the pathophysiological functions of Lp-PLA(2). Methods:Lp-PLA(2) knockout rabbits were generated using CRISPR/Cas9 system to assess the role of Lp-PLA(2) in plasma lipids regulation and identify its underlying molecular mechanisms. Homozygous knockout rabbits along with wild-type rabbits were fed a cholesterol-rich diet for up to 14 weeks and their atherosclerotic lesions were compared. Moreover, the effects of Lp-PLA(2) deficiency on the key cellular behaviors in atherosclerosis were assessed in vitro. Results:When rabbits were fed a standard diet, Lp-PLA(2) deficiency led to a significant reduction in plasma lipids. The decreased protein levels of SREBP2 (sterol regulatory element-binding protein 2) and HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase) in livers of homozygous knockout rabbits indicated that the cholesterol biosynthetic pathway was impaired with Lp-PLA(2) deficiency. In vitro experiments further demonstrated that intracellular Lp-PLA(2) efficiently enhanced SREBP2-related cholesterol biosynthesis signaling independently of INSIGs (insulin-induced genes). When fed a cholesterol-rich diet, homozygous knockout rabbits exhibited consistently lower level of hypercholesterolemia, and their aortic atherosclerosis lesions were significantly reduced by 60.2% compared with those of wild-type rabbits. The lesions of homozygous knockout rabbits were characterized by reduced macrophages and the expression of inflammatory cytokines. Macrophages of homozygous knockout rabbits were insensitive to M1 polarization and showed reduced DiI-labeled lipoprotein uptake capacity compared with wild-type macrophages. Lp-PLA(2) deficiency also inhibited the adhesion between monocytes and endothelial cells. Conclusions:These results demonstrate that Lp-PLA(2) plays a causal role in regulating blood lipid homeostasis and Lp-PLA(2) deficiency protects against dietary cholesterol-induced atherosclerosis in rabbits. Lp-PLA(2) could be a potential target for the prevention of atherosclerosis.
引用
收藏
页码:E11 / E28
页数:18
相关论文
共 50 条
  • [41] The Role of Lipoprotein-Associated Phospholipase A2 (Lp-PLA(2)) in Cardiovascular Disease
    Ikonomidis, Ignatios
    Michalakeas, Christos A.
    Lekakis, John
    Parissis, John
    Anastasiou-Nana, Maria
    REVIEWS ON RECENT CLINICAL TRIALS, 2011, 6 (02) : 108 - 113
  • [42] Lipoprotein-associated phospholipase A2 (Lp-PLA2) - possible diagnostic and risk biomarker in chronic ischaemic heart disease
    Diaconu, Adriana
    Coculescu, Bogdan-Ioan
    Manole, Gheorghe
    Vultur, Horaiiu
    Coculescu, Elena Claudia
    Stocheci, Cristina Maria
    Tudorache, Ioan-Sorin
    Dinca, Alexandra-Ligia
    Dinca, Valeriu Gabi
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2021, 36 (01) : 68 - 73
  • [43] "SI: PAF" Oxidized phospholipids and lipoprotein-associated phospholipase A2 (Lp-PLA2) in atherosclerotic cardiovascular disease: An update
    Pantazi, Despoina
    Tellis, Constantinos
    Tselepis, Alexandros D.
    BIOFACTORS, 2022, 48 (06) : 1257 - 1270
  • [44] Role of Lipoprotein-Associated Phospholipase A2 in Atherosclerosis
    Lavi, Shahar
    Herrmann, Joerg
    Lavi, Ronit
    McConnell, Joseph P.
    Lerman, Lilach O.
    Lerman, Amir
    CURRENT ATHEROSCLEROSIS REPORTS, 2008, 10 (03) : 230 - 235
  • [45] Role of lipoprotein-associated phospholipase A2 in atherosclerosis
    Shahar Lavi
    Joerg Herrmann
    Ronit Lavi
    Joseph P. McConnell
    Lilach O. Lerman
    Amir Lerman
    Current Atherosclerosis Reports, 2008, 10
  • [46] Lipoprotein-associated phospholipase A2 (Lp-PLA2) and tumor necrosis factor-alpha (TNF-α) and their relation to premature atherosclerosis in β-thalassemia children
    Ragab, Seham M.
    Safan, Manal A.
    Obeid, Osama M.
    Sherief, Asmaa S.
    HEMATOLOGY, 2015, 20 (04) : 228 - 238
  • [47] Lipoprotein-associated phospholipase A2 (Lp-PLA2), a vascular inflammation marker, is frequently increased in patients presenting with acute pericarditis
    Izhaki, A.
    Boaz, M.
    Chaimy, T.
    Abuhav, Y.
    Roitelman, J.
    Rozenman, Y.
    EUROPEAN HEART JOURNAL, 2015, 36 : 794 - 794
  • [48] Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2)
    Woolford, Alison J. -A.
    Day, Philip J.
    Beneton, Veronique
    Berdini, Valerio
    Coyle, Joseph E.
    Dudit, Yann
    Grondin, Pascal
    Huet, Pascal
    Lee, Lydia Y. W.
    Manas, Eric S.
    McMenamin, Rachel L.
    Murray, Christopher W.
    Page, Lee W.
    Patel, Vipulkumar K.
    Potvain, Florent
    Rich, Sharna J.
    Sang, Yingxia
    Somers, Don O.
    Trottet, Lionel
    Wan, Zehong
    Zhang, Xiaomin
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (23) : 10738 - 10749
  • [49] THE EFFECT OF NICOTINIC ACID/LAROPIPRANT ADMINISTRATION ON THE LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) ACTIVITY IN PATIENTS WITH MIXED DYSLIPIDEMIA
    Kei, A.
    Liberopoulos, E.
    Tellis, K.
    Rizos, C.
    Tselepis, A.
    Elisaf, M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 168 - 168
  • [50] Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients
    Rosing, Katharina
    Fobker, Manfred
    Kannenberg, Frank
    Gunia, Stefan
    Dell'Aquila, Angelo Maria
    Kwiecien, Robert
    Stypmann, Joerg
    Nofer, Jerzy-Roch
    ATHEROSCLEROSIS, 2013, 230 (01) : 164 - 170